Skip to content
Avantor logo

Avantor

AVTR

Avantor is a leading global provider of mission-critical products and services for the biopharma, healthcare, education, and advanced technology sectors.

Market cap
$8.48B-9.8%
Revenue$6.6B-1.6%
Net income-$630.4M-192%
Free cash flow$454.7M-18.2%
EPS (diluted)-$0.83-180%
Trailing twelve months · change vs. prior year

Earnings

Next report

Date not yet announced

Financials

Q2 2026

Income statement

See full
Revenue$1.7B+0.5%
Gross profit$537.0M-3.1%
Operating income$121.8M-5.4%
Net income$38.1M-41.1%
EPS (diluted)$0.06-33.3%

Balance sheet

See full
Cash & equivalents$309.7M-31.5%
Total debt$3.7B-12.8%
Total equity$5.6B-10.4%
Total assets$11.6B-9.2%

Cash flow

See full
Operating cash flow$178.2M+15.4%
CapEx$37.6M+27.0%
Free cash flow$140.6M+12.7%

Valuation & ratios

Valuation

See full
Market cap$8.48B-9.8%
Enterprise value$11.87B-11.0%
P/S1.3×-0.1×

Profitability

See full
Gross margin31.8%-1.4pp
Net margin-9.6%-19.9pp
FCF margin6.9%-1.4pp

Returns & leverage

See full
Return on equity-10.6%-22.3pp
Debt / equity0.7×0.0×
Current ratio1.8×+0.8×

Segments

By segment

See full
VWR Distribution & Services$1.2B+2.7%
Bioscience & Medtech Products$451.8M-5.1%

By product

See full
Proprietary$880.4M-1.5%
Third-party$811.9M+2.8%

Competitors

Profile

Avantor is a leading global provider of mission-critical products and services for the biopharma, healthcare, education, and advanced technology sectors. The company supports the entire scientific lifecycle from discovery to delivery, embedding its proprietary chemicals and materials into customer research and production workflows. Its value proposition centers on high-purity manufacturing and a massive distribution network that ensures regulatory compliance and operational efficiency for science-driven industries.

Competitive position

Avantor maintains a leading position through its dual-threat model of proprietary high-purity manufacturing and the globally recognized VWR distribution channel.

GeographiesGlobal, North America, Europe, Asia
Customer segmentsBiopharma, Healthcare, Education, Government, Advanced Technologies
Business modelManufacturing, Distribution, B2B E-commerce, Professional Services
SuppliersRaw chemical suppliers, Life science equipment manufacturers, Silicone feedstock providers
CustomersPharmaceutical companies, Clinical research organizations, University research labs, Medical implant manufacturers
Listed2019
Employees14.5K
CEOEmmanuel Ligner
FilingsSEC EDGAR

Questions, answered.

What is Avantor's market cap?
Avantor (AVTR) has a market capitalization of $8.5B and trades on NYSE.
What is Avantor's revenue and profitability?
Avantor generated $6.6B in trailing twelve-month revenue with a net loss of $630.4M, representing a net margin of -9.6%. Gross margin stands at 31.8%, with free cash flow of $454.7M. These figures are based on the Q2 2026 filing.
Who are Avantor's competitors?
Avantor's key competitors include Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, and others. These companies compete in similar markets and product categories.
What subsidiaries does Avantor have?
Avantor's subsidiaries include VWR, NuSil, Masterflex, and others.
Where is Avantor headquartered?
Avantor is headquartered in United States of America and employs approximately 14,500 people. It has been publicly traded since 2019.